Free Trial
OTCMKTS:RHHBY

Roche (RHHBY) Stock Price, News & Analysis

Roche logo
$41.83 +0.09 (+0.22%)
As of 03/3/2025 04:00 PM Eastern

About Roche Stock (OTCMKTS:RHHBY)

Key Stats

Today's Range
$41.73
$42.30
50-Day Range
$34.88
$42.04
52-Week Range
$29.20
$42.43
Volume
1.66 million shs
Average Volume
2.90 million shs
Market Capitalization
$266.79 billion
P/E Ratio
N/A
Dividend Yield
2.01%
Price Target
N/A
Consensus Rating
Moderate Buy

Company Overview

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Receive RHHBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter.

RHHBY Stock News Headlines

Viking Therapeutics company logo displayed on mobile phone
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval? (RHHBY)
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.
Jeff Brown's Urgent March 17th Alert
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Roche’s Genetech announces data from Phase III OUtMATCH study
See More Headlines

RHHBY Stock Analysis - Frequently Asked Questions

Roche's stock was trading at $34.88 at the beginning of the year. Since then, RHHBY stock has increased by 19.9% and is now trading at $41.83.
View the best growth stocks for 2025 here
.

Roche subsidiaries include these companies: Inflazome, Stratos Genomics, Promedior, Spark Therapeutics, Tusk Therapeutics, Flatiron Health, Ignyta, and more.

Roche's top institutional shareholders include Aristotle Capital Management LLC (0.04%), Saratoga Research & Investment Management (0.03%), Boston Common Asset Management LLC and OLD National Bancorp IN.

Shares of RHHBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
3/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Personal Services
Current Symbol
OTCMKTS:RHHBY
CIK
N/A
Employees
103,605
Year Founded
1896

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
14.89
P/E Growth
2.18
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$68.73 billion
Cash Flow
$3.26 per share
Price / Cash Flow
12.82
Book Value
$5.81 per share
Price / Book
7.20

Miscellaneous

Outstanding Shares
6,377,936,000
Free Float
N/A
Market Cap
$266.79 billion
Optionable
Not Optionable
Beta
0.42

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (OTCMKTS:RHHBY) was last updated on 3/4/2025 by MarketBeat.com Staff
From Our Partners